eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2018
vol. 69
 
Share:
Share:
more
 
 
abstract:
Original paper

Searching for new breast cancer-associated genes. ABRAXAS1 gene mutations in the group of BRCA1-negative patients

Aneta Bąk, Anna Junkiert-Czarnecka, Marta Heise, Daria Januchowska, Olga Krzywińska, Olga Haus

Pol J Pathol 2018; 69 (4): 342-346
Online publish date: 2019/01/31
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
In the present study, we analysed the association of mutations of a BRCA1-associated gene, ABRAXAS1, with the risk of development of breast cancer (BC) in BRCA1-negative women from North-Central Poland. A hundred women with consecutively diagnosed BC and 100 women belonging to the control group were screened for new mutations predisposing to breast cancer. The first step was a test carried out in order to find one of the three Polish founder mutations in the BRCA1 gene. In 96 BRCA1-negative patients two missense variants: c.422C>T and c.1042G>A as well as two intronic variants: IVS3-34G>A, IVS3-44T>C were detected in the ABRAXAS1 gene. The c.422C>T mutation was detected in one of 96 women diagnosed with breast cancer (1.04%); it was not associated with increased risk of disease in this group, compared to the controls (p = 0.49), but the odds ratio was 3.314; 95% CI: 0.122-75.352. IVS3-44T>C was found more frequently in the control group (15/93) than in the tested group (1/85),

OR 0.062; 95% CI: 0.008-0.480, p = 0.007, which may suggest protective properties of this variant against tumorigenicity. The data obtained from the present study suggest the necessity for further research to be conducted on the ABRAXAS1 gene in relation to hereditary predisposition to breast cancer.
keywords:

breast cancer, ABRAXAS1 mutations, breast cancer predisposing genes

references:
Garehdaghchi Z, Derakhshan MS, Khaniani SM. Evaluation of a newly discovered breast cancer susceptibility locus at 6q25.1 in Iranian Azari-Turkish women. Contemp Oncol (Pozn) 2016; 20: 308-310.
Nikkila J, Coleman KA, Morrissey D, et al. Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function. Oncogene 2009; 23: 1843-1852.
Nagy Z, Kalousi A, Furst A, et al. Tankyrases promote homologous recombination and check point activation in response to DSBs. PLoS Genet 2016; 12: e1005791.
Khabaz MN. Polymorphism of the glutathione S-transferase PI gene (GST-PI) in breast carcinoma. Pol J Pathol 2014; 65: 141-146.
Wang B, Matsuoka S, Ballif BA, et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007; 316: 1194-1198.
Solyom S, Aressy B, Pylkas K, et al. Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions. Sci Transl Med 2012; 4: 122-140.
Castillo A, Paul A, Sun B, et al. The BRCA1-interacting protein Abraxas is required for genomic stability and tumor suppression. Cell Rep 2014; 7: 807-817.
Liu Z, Wu J, Yu X. CCDC98 targets BRCA1 to DNA damage sites. Nat Struct Mol Biol 2007; 14: 716-720.
Lubiñski J, Huzarski T, Byrski T, et al.; Hereditary Breast Cancer Clinical Study Group. The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. Int J Cancer 2012; 131: 229-234.
Gronwald J, Lubiñski J. Clinical genetics of breast and ovary cancer. In: Clinical genetics of cancers 2017. Lubiñski J (ed.). Print Group Sp. z.o.o., Szczecin 2017; 85-109.
Górski B, Byrski T, Huzarski T, et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 2000; 66: 1963-1968.
Novak DJ, Sabbaghian N, Maillet P, et al. Analysis of the genes coding for the BRCA1 interacting proteins, RAP80 and Abraxas (CCDC98), in high-risk, non-BRCA1/2, multiethnic breast cancer cases. Breast Cancer Res Treat 2008; 117: 453-459.
Choi Y. A fast computation of pairwise sequence alignment scores between a protein and a set of single-locus variants of another protein. In: Proceedings of the ACM Conference on Bioinformatics, Computational Biology and Biomedicine. Orlando, 08-10.10.2012; 414-417.
Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249.
Tavtigian SV, Deffenbaugh AM, Yin L, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006; 43: 295-305.
Górski B, Cybulski C, Huzarski T, et al. Breast cancer predisposing alleles in Poland. Cancer Res Treat 2005; 92: 19-24.
Valcovici M, Andrica F, Serban C, et al. Cardiotoxicity of anthracycline therapy: current perspectives. Arch Med Sci 2016; 12: 428-435.
Renault AL, Lesueur F, Coulombe Y, et al. ABRAXAS
(FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry. PLoS One 2016; 7: 11: e0156820.
Osorio A, Barroso A, Garcia MJ, et al. Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility. Breast Cancer Res Treat 2009; 113: 371-376.
FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe